[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636860":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":152,"collaborators":19,"id":154,"slug":19,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":19,"eligibilityCriteria":159,"healthyVolunteers":155,"sex":160,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":19,"studyType":166,"phases":167,"briefSummary":169,"conditions":170,"keywords":19,"overallStatus":53,"whyStopped":19,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LY4256984","EXPERIMENTAL","LY4256984 administered intrathecally (IT)",[13],"Drug: LY4256984",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered IT",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Physicians interested in becoming principal investigators please contact","3176154559","clinical_inquiry_hub@lilly.com",[35,51,65,77,90,102,114,127,140],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UZ Leuven","NOT_YET_RECRUITING","Leuven","3000","Belgium",{"type":42,"coordinates":43},"Point",[44,45],4.70093,50.87959,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":19,"phoneExt":19,"email":19},"Philip Van Damme","PRINCIPAL_INVESTIGATOR",{"facility":52,"status":53,"city":54,"state":19,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"McGill University Health Centre","RECRUITING","Montreal","H4A 3J1","Canada",{"type":42,"coordinates":58},[59,60],-73.58781,45.50884,{"lat":60,"lon":59},[63],{"name":64,"role":50,"phone":19,"phoneExt":19,"email":19},"Angela Genge",{"facility":66,"status":37,"city":67,"state":19,"zip":68,"country":56,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Sunnybrook Research Institute","Toronto","M4N 3M5",{"type":42,"coordinates":70},[71,72],-79.39864,43.70643,{"lat":72,"lon":71},[75],{"name":76,"role":50,"phone":19,"phoneExt":19,"email":19},"Agessandro Abrahao",{"facility":78,"status":37,"city":79,"state":19,"zip":80,"country":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Universitätsklinikum Schleswig-Holstein","Lübeck","23538","Germany",{"type":42,"coordinates":83},[84,85],10.68729,53.86893,{"lat":85,"lon":84},[88],{"name":89,"role":50,"phone":19,"phoneExt":19,"email":19},"Julian Grosskreutz",{"facility":91,"status":37,"city":92,"state":19,"zip":93,"country":81,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Universitätsmedizin Rostock","Rostock","18147",{"type":42,"coordinates":95},[96,97],12.14049,54.0887,{"lat":97,"lon":96},[100],{"name":101,"role":50,"phone":19,"phoneExt":19,"email":19},"Andreas Hermann",{"facility":103,"status":37,"city":104,"state":19,"zip":105,"country":81,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Universitaetsklinikum Ulm","Ulm","89081",{"type":42,"coordinates":107},[108,109],9.99155,48.39841,{"lat":109,"lon":108},[112],{"name":113,"role":50,"phone":19,"phoneExt":19,"email":19},"Jochen Weishaupt",{"facility":115,"status":37,"city":116,"state":19,"zip":117,"country":118,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Universitair Medisch Centrum Utrecht","Utrecht","3584 CX","Netherlands",{"type":42,"coordinates":120},[121,122],5.12222,52.09083,{"lat":122,"lon":121},[125],{"name":126,"role":50,"phone":19,"phoneExt":19,"email":19},"Leonard H. Berg",{"facility":128,"status":37,"city":129,"state":19,"zip":130,"country":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Hospital Universitari de Bellvitge","L'Hospitalet de Llobregat","08907","Spain",{"type":42,"coordinates":133},[134,135],2.10028,41.35967,{"lat":135,"lon":134},[138],{"name":139,"role":50,"phone":19,"phoneExt":19,"email":19},"MONICA POVEDANO PANADES",{"facility":141,"status":37,"city":142,"state":19,"zip":143,"country":131,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Hospital Universitari i Politecnic La Fe","Valencia","46026",{"type":42,"coordinates":145},[146,147],-0.37966,39.47391,{"lat":147,"lon":146},[150],{"name":151,"role":50,"phone":19,"phoneExt":19,"email":19},"Juan Vazquez-Costa",{"type":153,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100636860",false,"NCT07571174","A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis","A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA","Participants must meet eligibility criteria in the \\[L0U-MC-OLMP\\] screening protocol before entry into the treatment study.\n\nInclusion Criteria:\n\n* Have completed the main treatment period\u002Fphase as well as any off-treatment period\u002Fphase of Study OWAA, the parent study for this ISA.\n\nExclusion Criteria:\n\n* The participant has conditions that preclude a lumbar puncture (LP), such as:\n\n  * A history of clinically significant back pain, back pathology, and\u002For back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose to complications or technical difficulty with LP.\n  * Allergy to local anesthetics, such as lidocaine or its derivatives.\n  * A local infection at the intended site of the LP.\n  * Less than 100 giga per liter \\[(\\\u003C100 GI\u002FL) is equivalent to 100,000 per cubic millimeter (100,000\u002Fmm³)\\] platelets or clinically significant coagulation abnormality or significant active bleeding, or\n  * Currently receiving treatment with an anticoagulant, antiplatelet agent, or other drug that affects coagulation or platelet function. Low dose (according to local medical guidelines) aspirin is permitted.","ALL","18 Years","80 Years",{"count":164,"type":165},32,"ESTIMATED","INTERVENTIONAL",[168],"PHASE1","The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.",[171],"Amyotrophic Lateral Sclerosis","2026-06-19",{"date":174,"type":175},"2026-06-24","ACTUAL",{"date":177,"type":175},"2026-05-14",{"date":179,"type":165},"2029-06",{"name":5,"class":6},9]